PharmaMar

Founded in 1986, PharmaMar a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, the rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. Also, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company is headquartered in Madrid, Spain.